Open Access

REVIEW

SAYUMI TAHARA¹, SYDNEY RENTSCH¹, FERNANDA COSTAS CASAL DE FARIA¹, PATRICIA SARCHET¹, ROMA KARNA¹, FEDERICA CALORE^2,*, RAPHAEL E. POLLOCK¹
Oncology Research, Vol.33, No.1, pp. 1-13, 2025, DOI:10.32604/or.2024.053635 - 20 December 2024
Abstract Liposarcoma is one of the most common soft tissue sarcomas, however, its occurrence rate is still rare compared to other cancers. Due to its rarity, in vitro experiments are an essential approach to elucidate liposarcoma pathobiology. Conventional cell culture-based research (2D cell culture) is still playing a pivotal role, while several shortcomings have been recently under discussion. In vivo, mouse models are usually adopted for pre-clinical analyses with expectations to overcome the issues of 2D cell culture. However, they do not fully recapitulate human dedifferentiated liposarcoma (DDLPS) characteristics. Therefore, three-dimensional (3D) culture systems have been the recent… More >

View

219

Download

48

Open Access

REVIEW

SOROUSH SOLEYMANI¹, MOHAMMAD DOROUDIAN^2,*, MAHDIEH SOEZI^3,4, ALI BELADI⁵, KIARASH ASGARI², ASO MOBARAKSHAHI², ARYANA AGHAEIPOUR², RONAN MACLOUGHLIN^6,7,8,*
Oncology Research, Vol.33, No.1, pp. 15-26, 2025, DOI:10.32604/or.2024.053069 - 20 December 2024
Abstract Brain metastasis and primary glioblastoma multiforme represent the most common and lethal malignant brain tumors. Its median survival time is typically less than a year after diagnosis. One of the major challenges in treating these cancers is the efficiency of the transport of drugs to the central nervous system. The blood-brain barrier is cooperating with advanced stages of malignancy. The blood-brain barrier poses a significant challenge to delivering systemic medications to brain tumors. Nanodrug delivery systems have emerged as promising tools for effectively crossing this barrier. Additionally, the development of smart nanoparticles brings new hope More >

View

411

Download

83

Open Access

REVIEW

MERYEM A. ABDESSALEM, SIRIN A. ADHAM^*
Oncology Research, Vol.33, No.1, pp. 27-44, 2025, DOI:10.32604/or.2024.056955 - 20 December 2024
Abstract Nanotechnology in cancer therapy has significantly advanced treatment precision, effectiveness, and safety, improving patient outcomes and personalized care. Engineered smart nanoparticles and cell-based therapies are designed to target tumor cells, precisely sensing the tumor microenvironment (TME) and sparing normal cells. These nanoparticles enhance drug accumulation in tumors by solubilizing insoluble compounds or preventing their degradation, and they can also overcome therapy resistance and deliver multiple drugs simultaneously. Despite these benefits, challenges remain in patient-specific responses and regulatory approvals for cell-based or nanoparticle therapies. Cell-based drug delivery systems (DDSs) that primarily utilize the immune-recognition principle between… More >

Graphic Abstract

View

202

Download

42

Open Access

ARTICLE

ENRICO CALIMAN^1,2, SARA FANCELLI^1,2, FEDERICO SCOLARI³, ADRIANO PASQUI⁴, CLARA MANNESCHI⁴, DANIELE LAVACCHI¹, FRANCESCA MAZZONI⁴, FRANCESCA GENSINI⁵, VALERIA PASINI⁶, CAMILLA EVA COMIN^2,7, LUCA VOLTOLINI^2,8, SERENA PILLOZZI^1,2,*, LORENZO ANTONUZZO^1,2,4
Oncology Research, Vol.33, No.1, pp. 45-55, 2025, DOI:10.32604/or.2024.050161 - 20 December 2024
（This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
Abstract Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2,… More >

View

565

Download

83

Open Access

ARTICLE

RYUL KIM^1,#, JOO KYUNG PARK^2,#, MINSUK KWON³, MINAE AN⁴, JUNG YONG HONG¹, JOON OH PARK¹, SUNG HEE LIM^1,*, SEUNG TAE KIM^1,*
Oncology Research, Vol.33, No.1, pp. 57-65, 2025, DOI:10.32604/or.2024.049054 - 20 December 2024
Abstract Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC) are still controversial. Materials and methods: We molecularly characterized tissues and blood from 32 patients with metastatic BTC treated with the ICI pembrolizumab as second-line therapy. Results: All patients had microsatellite stable (MSS) type tumors. Three of the 32 patients achieved partial response (PR), with an objective response rate (ORR) of 9.4% (95% confidence interval [CI], 2.0–25.2) and nine showed stable disease (SD), exhibiting a disease… More >

View

193

Download

32

Open Access

ARTICLE

XIANG LI^1,#, WENKE JIN^2,#, LIFENG WU², HUAN WANG¹, XIN XIE¹, WEI HUANG^1,*, BO LIU^2,*
Oncology Research, Vol.33, No.1, pp. 67-81, 2025, DOI:10.32604/or.2024.055921 - 20 December 2024
Abstract Background: Triple-negative breast cancer (TNBC), characterized by its lack of traditional hormone receptors and HER2, presents a significant challenge in oncology due to its poor response to conventional therapies. Autophagy is an important process for maintaining cellular homeostasis, and there are currently autophagy biomarkers that play an effective role in the clinical treatment of tumors. In contrast to targeting protein activity, intervention with protein-protein interaction (PPI) can avoid unrelated crosstalk and regulate the autophagy process with minimal interference pathways. Methods: Here, we employed Naive Bayes, Decision Tree, and k-Nearest Neighbors to elucidate the complex PPI… More >

View

233

Download

62

Open Access

ARTICLE

YUEZHOU ZHANG^1,#, ZHAO ZHANG^2,#, JINXIN DONG¹, CHANGAN LIU^1,*
Oncology Research, Vol.33, No.1, pp. 83-102, 2025, DOI:10.32604/or.2024.055866 - 20 December 2024
Abstract Background: Aberrant expression of RNA-binding proteins (RBPs) has been linked to a variety of diseases, including hematological disorders, cardiovascular diseases, and multiple types of cancer. Heterogeneous nuclear ribonucleoprotein C (HNRNPC), a member belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family, plays a pivotal role in nucleic acid metabolism. Previous studies have underscored the significance of HNRNPC in tumorigenesis; however, its specific role in malignant tumor progression remains inadequately characterized. Methods: We leveraged publicly available databases, including The Cancer Genome Atlas (TCGA), to explore the potential involvement of HNRNPC across various cancers. Additionally, we performed experimental… More >

Graphic Abstract

View

225

Download

48

Open Access

ARTICLE

YAN LU^1,2,#, KANG WANG^3,#, YUANHONG PENG^3,4, MENG CHEN⁵, LIN ZHONG^3,4, LUJI HUANG^3,4, FU CHENG^3,4, XINDAN SHENG^4,6, XIN YANG^4,6, MANZHAO OUYANG^3,4, GEORGE A. CALIN^5,*, ZHIWEI HE^1,*
Oncology Research, Vol.33, No.1, pp. 103-121, 2025, DOI:10.32604/or.2024.057472 - 20 December 2024
Abstract Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear. Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases. MicroRNAs were selected using the… More >

View

38

Download

16

Open Access

ARTICLE

LEI WANG¹, XIANJIN XIE^2,*
Oncology Research, Vol.33, No.1, pp. 123-132, 2025, DOI:10.32604/or.2024.048562 - 20 December 2024
Abstract Background: To investigate SCL/TAL 1 interrupting locus (STIL)’s role and prognostic significance in lung adenocarcinoma (LUAD) progression, we examined STIL and E2 promoter binding factor 1 (E2F1) expression and their impacts on LUAD prognosis using Gene Expression Profiling Interactive Analysis (GEPIA). Methods: Functional assays including CCK-8, wound-healing, 5-ethynyl-2-deoxyuridine (EdU), Transwell assays, and flow cytometry, elucidated STIL and E2F1’s effects on cell viability, proliferation, apoptosis, and migration. Gene set enrichment analysis (GSEA) identified potential pathways, while metabolic assays assessed glucose metabolism. Results: Our findings reveal that STIL and E2F1 are overexpressed in LUAD, correlating with adverse outcomes. It enhances More >

View

608

Download

108

Open Access

ARTICLE

TAO SUN^1,2, QINGHUA SONG³, HUA LIU^1,*
Oncology Research, Vol.33, No.1, pp. 133-148, 2025, DOI:10.32604/or.2024.054141 - 20 December 2024
Abstract Background: Lung cancer is a life-threatening disease that occurs worldwide, but is especially common in China. The crucial role of the tumour microenvironment (TME) in non-small cell lung cancer (NSCLC) has attracted recent attention. Cancer-associated fibroblasts (CAFs) are the main factors that contribute to the TME function, and CAF exosomes are closely linked to NSCLC. Methods: The expression levels of miR-3124-5p and Toll-interacting protein (TOLLIP) were analysed by bioinformatics prediction combined with RT-qPCR/Western Blot detection. Fibroblasts were isolated and identified from clinical NSCLC tissues. Transmission electron microscopy and Western Blot were used to identify exosomes… More >

View

281

Download

54

Open Access

ARTICLE

NASSER MULLA^1,*, YOUSEF KATIB², ASIM M. ALMUGHAMSI³, DUAA S. ALKHAYAT¹, MOHAMED MOSAAD^1,4, SAMIR T. ALFOTIH⁵, RAWAN ALAOFI⁶
Oncology Research, Vol.33, No.1, pp. 149-160, 2025, DOI:10.32604/or.2024.050903 - 20 December 2024
Abstract Background: Hepatocellular carcinoma (HCC) is the most common cause of cancer-related death in Saudi Arabia. Our study aimed to investigate the patterns of HCC and the effect of TNM staging, Alfa-fetoprotein (AFP), and Child-Turcotte Pugh (CTP) on patients’ overall survival (OS). Methods: A retrospective analysis was conducted on 43 HCC patients at a single oncology center in Saudi Arabia from 2015 to 2020. All patients had to fulfill one of the following criteria: (a) a liver lesion reported as definitive HCC on dynamic imaging and/or (b) a biopsy-confirmed diagnosis. Results: The mean patient age of all… More >

View

288

Download

60

Open Access

ARTICLE

XIUWANG WEI¹, JIANBO LIANG¹, HUANWEN HUANG¹, DAMING YANG¹, XINXIN WANG¹, XIUJIA WANG¹, CHANGSHENG CHEN¹, KAIQIANG LI¹, TAISEN PANG¹, BIN HU¹, FENGNING WU^2,*
Oncology Research, Vol.33, No.1, pp. 161-169, 2025, DOI:10.32604/or.2024.048054 - 20 December 2024
Abstract Background: Transmembrane emp24 trafficking protein 3 (TMED3) is associated with the development of several tumors; however, whether TMED3 regulates the progression of prostate cancer remains unclear. Materials and Methods: Short hairpin RNA was performed to repress TMED3 in prostate cancer cells (DU145 cells) and in a prostate cancer mice model to determine its function in prostate cancer in vitro and in vivo. Results: In the present study, we found that TMED3 was highly expressed in prostate cancer cells. In vitro, shTMED3 treatment suppressed the proliferation, invasion, and migration and promoted the apoptosis of DU145 cells. Additionally, the Kyoto Encyclopedia… More >

View

624

Download

115

Open Access

ARTICLE

GENGYUN SUN^1,*, YIPING ZHENG^1,2, JIANFENG CAI², JIE GAO², LIE DONG², XIANGBIN ZHANG², YINGHUI HUANG^2,*
Oncology Research, Vol.33, No.1, pp. 171-184, 2025, DOI:10.32604/or.2024.047626 - 20 December 2024
（This article belongs to the Special Issue: Long noncoding RNAs as Tumorigenic Drivers and Therapeutic Targets)
Abstract Background: Long noncoding RNA, LINC01106 exhibits high expression in lung adenocarcinoma (LUAD) tumor tissues, but its functional role and regulatory mechanism in LUAD cells remain unclear. Methods: LINC01106 expression was analyzed in LUAD tissues and its functional impact on LUAD cells was assessed. LUAD cells were silenced with sh-LINC01106 and injected into nude mice to investigate tumor growth. The downstream transcription factors and molecular mechanism were determined using the Human transcription factor database (TFDB) database and Gene Expression Profiling Interactive Analysis (GEPIA) database. Additionally, the impact of linc01106 on autophagy was analyzed by determining the… More >

Graphic Abstract

View

711

Download

160

Open Access

ARTICLE

ZHOUYANG CHENG^1,#, YUCHEN HUA^2,#, YANG CAO³, JUN QIN^1,*
Oncology Research, Vol.33, No.1, pp. 185-198, 2025, DOI:10.32604/or.2024.042281 - 20 December 2024
（This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
Abstract Objective: Gastric cancer (GC) is a globally common cancer characterized by high incidence and mortality worldwide. Advances in the molecular understanding of GC provide promising targets for GC diagnosis and therapy. Long non-coding RNAs (lncRNAs) and their downstream regulators are regarded to be implicated in the progression of multiple types of malignancies. Studies have shown that the lncRNA small nucleolar RNA host gene 4 (SNHG4) serves as a tumor promoter in various malignancies, while its function in GC has yet to be characterized. Therefore, our study aimed to explore the role and underlying mechanism of… More >

View

685

Download

140

Open Access

ARTICLE

WEN YANG, BIN TANG, DAN XU, WENXIU YANG^*
Oncology Research, Vol.33, No.1, pp. 199-212, 2025, DOI:10.32604/or.2024.050036 - 20 December 2024
Abstract Background: The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma (DLBCL) has been reported previously. However, the detailed mechanisms of CCR7 in DLBCL, particularly regarding its interaction with lenalidomide treatment, are not fully understood. Methods: Our study utilized bioinformatics approaches to identify hub genes in SU-DHL-2 cell lines treated with lenalidomide compared to control groups. Immunohistochemical data and clinical information from 122 patients with DLBCL were analyzed to assess the correlation of CCR7 and p-ERK1/2 expression with the prognosis of DLBCL. Furthermore, in vitro and in vivo experiments were conducted to clarify the… More >

Graphic Abstract

View

553

Download

120

Open Access

ARTICLE

SHIQIN JIANG^1,#, YICHUN TANG^2,#, FENG MA³, YUCHUN NIU^4,*, LEI SUN^5,*
Oncology Research, Vol.33, No.1, pp. 213-224, 2025, DOI:10.32604/or.2024.046895 - 20 December 2024
Abstract Objective: Small cell lung cancer (SCLC) is commonly recognized as the most fatal lung cancer type. Despite substantial advances in immune checkpoint blockade therapies for treating solid cancers, their benefits are limited to a minority of patients with SCLC. In the present study, novel indicators for predicting the outcomes and molecular targets for SCLC treatment were elucidated. Methods: We conducted bioinformatics analysis to identify the key genes associated with tumor-infiltrating lymphocytes in SCLC. The functional role of the key gene identified in SCLC was determined both in vitro and in vivo. Results: A significant correlation was observed between… More >

View

580

Download

81

Open Access

ARTICLE

WEI ZHANG^1,3,#, WEICHENG WANG^1,#, RUI WANG¹, XIAO HAN¹, LIJUN ZHU¹, WENJIE GUO^2,*, YANHONG GU^1,*
Oncology Research, Vol.33, No.1, pp. 225-234, 2025, DOI:10.32604/or.2024.050047 - 20 December 2024
Abstract Background: As a novel blocker of vascular endothelial growth factor receptor (VEGFR), fruquintinib has been approved for treating colorectal cancer (CRC). However, its dosage and therapeutic efficacy are limited by its widespread adverse reactions. Venetoclax, recognized as the initial inhibitor of B-cell lymphoma protein 2 (BCL2), has shown potential in boosting the effectiveness of immunotherapy against CRC. This study investigated the efficacy and mechanisms of fruquintinib combined with venetoclax in treating CRC. Methods and Materials: We developed a colon cancer mouse model with the CT26 colon cell line to demonstrate fruquintinib and venetoclax’s efficacy against tumors.… More >

Graphic Abstract

View

705

Download

96

Open Access

ARTICLE

HASSAN M. OTIFI^*
Oncology Research, Vol.33, No.1, pp. 235-243, 2025, DOI:10.32604/or.2024.055677 - 20 December 2024
Abstract Background: Gastric cancer (GC) remains a global health burden and is often characterized by heterogeneous molecular profiles and resistance to conventional therapies. The phosphoinositide 3-kinase and PI3K and Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathways play pivotal roles in GC progression, making them attractive targets for therapeutic interventions. Methods: This study applied a computational and molecular dynamics simulation approach to identify and characterize SBL-JP-0004 as a potential dual inhibitor of JAK2 and PI3KCD kinases. KATOIII and SNU-5 GC cells were used for in vitro evaluation. Results: SBL-JP-0004 exhibited a robust binding affinity for… More >

View

138

Download

34